These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
186 related articles for article (PubMed ID: 32767352)
1. 1-trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl) urea (TPPU), a soluble epoxide hydrolase inhibitor, lowers L-NAME-induced hypertension through suppression of angiotensin-converting enzyme in rats. Bukhari IA; Alorainey BI; Al-Motrefi AA; Mahmoud A; Campbell WB; Hammock BD Eur Rev Med Pharmacol Sci; 2020 Aug; 24(15):8143-8150. PubMed ID: 32767352 [TBL] [Abstract][Full Text] [Related]
2. The contribution of chymase-dependent formation of ANG II to cardiac dysfunction in metabolic syndrome of young rats: roles of fructose and EETs. Froogh G; Kandhi S; Duvvi R; Le Y; Weng Z; Alruwaili N; Ashe JO; Sun D; Huang A Am J Physiol Heart Circ Physiol; 2020 Apr; 318(4):H985-H993. PubMed ID: 32167781 [TBL] [Abstract][Full Text] [Related]
3. 1-trifluoromethoxyphenyl-3(1-propionylpiperidin-4-yl) urea (TPPU), a soluble epoxide hydrolase inhibitor attenuates high fat diet-induced cardiovascular and metabolic disorders in rats. Bukhari IA; Mohamed OY; Mahmood A; Alfadda AA; Almotrefi AA Eur Rev Med Pharmacol Sci; 2021 Jan; 25(10):3835-3847. PubMed ID: 34109592 [TBL] [Abstract][Full Text] [Related]
4. 1-Trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl) Urea, a Selective and Potent Dual Inhibitor of Soluble Epoxide Hydrolase and p38 Kinase Intervenes in Alzheimer's Signaling in Human Nerve Cells. Liang Z; Zhang B; Xu M; Morisseau C; Hwang SH; Hammock BD; Li QX ACS Chem Neurosci; 2019 Sep; 10(9):4018-4030. PubMed ID: 31378059 [TBL] [Abstract][Full Text] [Related]
5. An omega-3 epoxide of docosahexaenoic acid lowers blood pressure in angiotensin-II-dependent hypertension. Ulu A; Stephen Lee KS; Miyabe C; Yang J; Hammock BG; Dong H; Hammock BD J Cardiovasc Pharmacol; 2014 Jul; 64(1):87-99. PubMed ID: 24691274 [TBL] [Abstract][Full Text] [Related]
6. Early antihypertensive treatment and ischemia-induced acute kidney injury. Greite R; Derlin K; Hensen B; Thorenz A; Rong S; Chen R; Hellms S; Jang MS; Bräsen JH; Meier M; Willenberg I; Immenschuh S; Haller H; Luft FC; Panigrahy D; Hwang SH; Hammock BD; Schebb NH; Gueler F Am J Physiol Renal Physiol; 2020 Oct; 319(4):F563-F570. PubMed ID: 32799675 [TBL] [Abstract][Full Text] [Related]
7. Angiotensin-converting enzyme inhibition and angiotensin AT1-receptor antagonism equally improve endothelial vasodilator function in L-NAME-induced hypertensive rats. De Gennaro Colonna V; Rigamonti A; Fioretti S; Bonomo S; Manfredi B; Ferrario P; Bianchi M; Berti F; Muller EE; Rossoni G Eur J Pharmacol; 2005 Jun; 516(3):253-9. PubMed ID: 15963975 [TBL] [Abstract][Full Text] [Related]
8. Antihypertensive and renoprotective actions of soluble epoxide hydrolase inhibition in ANG II-dependent malignant hypertension are abolished by pretreatment with L-NAME. Honetschlägerová Z; Kitada K; Husková Z; Sporková A; Kopkan L; Bürgelová M; Varcabová Š; Nishiyama A; Hwang SH; Hammock BD; Imig JD; Kramer HJ; Kujal P; Vernerová Z; Červenka L J Hypertens; 2013 Feb; 31(2):321-32. PubMed ID: 23307303 [TBL] [Abstract][Full Text] [Related]
10. Angiotensin type 1 receptor antagonism and ACE inhibition produce similar renoprotection in N(omega)-nitro-L>-arginine methyl ester/spontaneously hypertensive rats. Nakamura Y; Ono H; Zhou X; Frohlich ED Hypertension; 2001 May; 37(5):1262-7. PubMed ID: 11358938 [TBL] [Abstract][Full Text] [Related]
11. Inhibitors of soluble epoxide hydrolase minimize ischemia-reperfusion-induced cardiac damage in normal, hypertensive, and diabetic rats. Islam O; Patil P; Goswami SK; Razdan R; Inamdar MN; Rizwan M; Mathew J; Inceoglu B; Stephen Lee KS; Hwang SH; Hammock BD Cardiovasc Ther; 2017 Jun; 35(3):. PubMed ID: 28296232 [TBL] [Abstract][Full Text] [Related]
12. Soluble epoxide hydrolase inhibitor 1-trifluoromethoxyphenyl-3- (1-propionylpiperidin-4-yl) urea attenuates bleomycin-induced pulmonary fibrosis in mice. Zhou Y; Yang J; Sun GY; Liu T; Duan JX; Zhou HF; Lee KS; Hammock BD; Fang X; Jiang JX; Guan CX Cell Tissue Res; 2016 Feb; 363(2):399-409. PubMed ID: 26310139 [TBL] [Abstract][Full Text] [Related]
13. Effects of sEH inhibition on the eicosanoid and cytokine storms in SARS-CoV-2-infected mice. Edin ML; Gruzdev A; Graves JP; Lih FB; Morisseau C; Ward JM; Hammock BD; Bosio CM; Zeldin DC FASEB J; 2024 May; 38(10):e23692. PubMed ID: 38786655 [TBL] [Abstract][Full Text] [Related]
14. Pharmacological Inhibition of Soluble Epoxide Hydrolase Ameliorates Chronic Ethanol-Induced Cardiac Fibrosis by Restoring Autophagic Flux. Zhou C; Huang J; Li Q; Zhan C; He Y; Liu J; Wen Z; Wang DW Alcohol Clin Exp Res; 2018 Oct; 42(10):1970-1978. PubMed ID: 30047995 [TBL] [Abstract][Full Text] [Related]
15. Inhibition of soluble epoxide hydrolase offers protection against fructose-induced diabetes and related metabolic complications in rats. Shah SA; Mehmood MH; Khan M; Bukhari IA; Alorainey BI; Vohra F J Physiol Pharmacol; 2020 Oct; 71(5):. PubMed ID: 33475089 [TBL] [Abstract][Full Text] [Related]
16. A Soluble Epoxide Hydrolase Inhibitor, 1-TrifluoromethoxyPhenyl-3-(1-Propionylpiperidin-4-yl) Urea, Ameliorates Experimental Autoimmune Encephalomyelitis. Jonnalagadda D; Wan D; Chun J; Hammock BD; Kihara Y Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33925035 [TBL] [Abstract][Full Text] [Related]
17. Effect of imidapril on myocardial remodeling in L-NAME-induced hypertensive rats is associated with gene expression of NOS and ACE mRNA. Kobayashi N; Hara K; Watanabe S; Higashi T; Matsuoka H Am J Hypertens; 2000 Feb; 13(2):199-207. PubMed ID: 10701821 [TBL] [Abstract][Full Text] [Related]
18. Anti-inflammatory treatment with a soluble epoxide hydrolase inhibitor attenuates seizures and epilepsy-associated depression in the LiCl-pilocarpine post-status epilepticus rat model. Shen Y; Peng W; Chen Q; Hammock BD; Liu J; Li D; Yang J; Ding J; Wang X Brain Behav Immun; 2019 Oct; 81():535-544. PubMed ID: 31306773 [TBL] [Abstract][Full Text] [Related]
19. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Ferrario CM; Jessup J; Chappell MC; Averill DB; Brosnihan KB; Tallant EA; Diz DI; Gallagher PE Circulation; 2005 May; 111(20):2605-10. PubMed ID: 15897343 [TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and in vivo potency of soluble epoxide hydrolase inhibitors in cynomolgus monkeys. Ulu A; Appt S; Morisseau C; Hwang SH; Jones PD; Rose TE; Dong H; Lango J; Yang J; Tsai HJ; Miyabe C; Fortenbach C; Adams MR; Hammock BD Br J Pharmacol; 2012 Mar; 165(5):1401-12. PubMed ID: 21880036 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]